Reckitt Benckiser (RB) has this week opened a state-of-the-art Science and Innovation Centre in Hull, and reaffirmed its commitment to investing in the UK.
The consumer goods giant stated that the S&I Centre, equipped with new consumer health laboratory facilities, is the first milestone of its ongoing £200m investment programme in the city. Alongside the new centre, RB is committing £95m to upgrade the manufacturing facilities on the Hull site, which employs around 1,400 people.
One of six major RB R&D facilities worldwide, the new UK S&I Centre will be the global technical innovation hub for household name consumer health products such as Nurofen and Strepsils. The company said the site is expected to act as a magnet for the best scientific talent globally and locally with 200 new jobs created.
Laxman Narasimhan, CEO of RB, commented: “Despite the current macro-economic uncertainty in the UK, it is our firm belief that our new centre will help the country further develop its scientific talent and R&D credentials. It underlines our view that the UK is the best place to invest in consumer health R&D.”
